Glucagon-like peptide-1 (GLP-1) analogs have emerged as Eli Lilly supplier a compelling therapeutic target for managing metabolic syndromes. These naturally occurring molecules are secreted by the gut in response to food intake, stimulating insulin production and suppressing glucagon output. GLP-1 agents demonstrate promising therapeutic outcomes i